Panoramica dell'azienda
Establishment Labs Holdings Inc. operates as a medical technology enterprise dedicated to the manufacturing and marketing of medical devices specifically designed for breast aesthetic and reconstructive plastic surgeries. The company serves a global footprint that includes Europe, the Middle East, Africa, Latin America, Asia, and the United States, positioning itself within the broader Healthcare sector under the Medical Devices industry classification. This sector designation implies that the company's performance is intrinsically linked to advancements in surgical technology and regulatory standards governing medical equipment rather than consumer discretionary spending patterns. In terms of scale, Establishment Labs Holdings Inc. commands a market capitalization of $1.82B and generates annual revenue of $211.08M, while employing a workforce of 1004 individuals. These valuation and revenue figures indicate that the company has established a significant presence in its niche, suggesting a mature operation capable of sustaining operations without reliance on a single small-market segment, though the high valuation relative to earnings warrants careful analysis of its growth sustainability.
Salute finanziaria
The company reports a revenue figure of $211.08M for the trailing twelve months, yet it posts a net income of $-51,064,000 and an EBITDA of $-29,445,000, revealing a substantial gap between top-line generation and bottom-line profitability that points to a cost structure where expenses significantly outweigh operational earnings. This negative earnings trajectory is further evidenced by a free cash flow of $-41,574,000, which indicates that the company is currently burning cash and lacks the immediate financial flexibility to fund operations solely through internal cash generation without external capital infusion. The margin profile illustrates a gross margin of 69.3%, which suggests strong pricing power or cost advantages in production, contrasted sharply by an operating margin of -6.1% and a profit margin of -24.2%, indicating that high operational costs, likely related to research and development or sales expenses, are eroding the gross profits. Regarding liquidity and leverage, the company holds $75.57M in cash against total debt of $264.47M, resulting in a debt-to-equity ratio of 1123.14, which characterizes the balance sheet as highly leveraged and dependent on equity issuance or refinancing to meet obligations. Short-term liquidity appears robust given a current ratio of 3.04, which suggests the company possesses more than three times the liquid assets necessary to cover its current liabilities, though this must be weighed against the long-term debt burden. Return metrics show a return on equity of -133.3% and a return on assets of -6.9%, revealing that management effectiveness is currently negative as the company destroys shareholder value and utilizes assets inefficiently to generate profit in the current fiscal period.
Valutazione del valore
Valuation multiples present a complex picture, with a trailing P/E ratio listed as N/A due to negative earnings, while the forward P/E stands at 302.73, implying that the market expects a dramatic turnaround in earnings to justify the current stock price in the coming year. The price-to-book ratio is elevated at 77.19, indicating that the market is pricing the company at a massive premium over its book value, which often occurs in high-growth biotech or medtech firms but carries significant risk if growth expectations are not met. Alternative valuation metrics such as a price-to-sales ratio of 8.62 and an EV/EBITDA of -68.21 suggest that traditional value investing metrics are less applicable, as the negative EV/EBITDA reflects the current unprofitability and high enterprise value relative to negative cash flows. Technical price levels show a 52-week high of $83.31 and a 52-week low of $26.56; assuming the current market dynamics align with the provided forward P/E context, the stock is trading at a level that represents a significant deviation from its recent lows, highlighting the volatility inherent in its valuation. The beta value of 1.08 indicates that the stock's price volatility is slightly higher than the broader market, meaning that for every 1% move in the general market index, Establishment Labs Holdings Inc. is expected to move approximately 1.08%, reflecting moderate sensitivity to macroeconomic shifts.
Growth & Income
Revenue growth for the trailing twelve months stands at 45.2%, while earnings growth is listed as N/A due to the company's current losses, implying that top-line expansion is outpacing profitability in a typical growth-stage scenario where reinvestment suppresses current earnings. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, which is recorded as 0.0%, indicating that all available capital is being retained and reinvested directly into operational growth, R&D, or debt reduction rather than distributed to shareholders. This reinvestment strategy is typical for medical device companies in the development phase, where capital expenditure is prioritized over income distribution to secure market share and technological leadership. Overall, the growth and income profile is defined by aggressive top-line expansion coupled with a complete absence of current profitability and shareholder returns, creating a high-risk, high-potential-return dynamic where future valuation hinges entirely on the speed of turning the current negative earnings trajectory into positive cash flow.